196 related articles for article (PubMed ID: 37879169)
1. Advances in research on potential inhibitors of multiple myeloma.
Tang G; Huang S; Luo J; Wu Y; Zheng S; Tong R; Zhong L; Shi J
Eur J Med Chem; 2023 Dec; 262():115875. PubMed ID: 37879169
[TBL] [Abstract][Full Text] [Related]
2. Proteasome inhibitors for multiple myeloma.
Okazuka K; Ishida T
Jpn J Clin Oncol; 2018 Sep; 48(9):785-793. PubMed ID: 30102324
[TBL] [Abstract][Full Text] [Related]
3. Novel investigational drugs active as single agents in multiple myeloma.
D'Agostino M; Salvini M; Palumbo A; Larocca A; Gay F
Expert Opin Investig Drugs; 2017 Jun; 26(6):699-711. PubMed ID: 28448171
[TBL] [Abstract][Full Text] [Related]
4. Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma.
Podar K; Pecherstorfer M
Expert Opin Pharmacother; 2017 Aug; 18(11):1061-1079. PubMed ID: 28604120
[TBL] [Abstract][Full Text] [Related]
5. Contemporary drug therapies for multiple myeloma.
de la Puente P; Azab AK
Drugs Today (Barc); 2013 Sep; 49(9):563-73. PubMed ID: 24086952
[TBL] [Abstract][Full Text] [Related]
6. Research strategies of small molecules as chemotherapeutics to overcome multiple myeloma resistance.
Yang J; Yu YC; Wang ZX; Li QQ; Ding N; Leng XJ; Cai J; Zhang MY; Wang JJ; Zhou Y; Wei TH; Xue X; Dai WC; Sun SL; Yang Y; Li NG; Shi ZH
Eur J Med Chem; 2024 May; 271():116435. PubMed ID: 38648728
[TBL] [Abstract][Full Text] [Related]
7. Resistance to proteasome inhibitors and other targeted therapies in myeloma.
Wallington-Beddoe CT; Sobieraj-Teague M; Kuss BJ; Pitson SM
Br J Haematol; 2018 Jul; 182(1):11-28. PubMed ID: 29676460
[TBL] [Abstract][Full Text] [Related]
8. Advances in targeted therapy for the treatment of patients with relapsed/refractory multiple myeloma.
Le Ray E; Jagannath S; Palumbo A
Expert Rev Hematol; 2016 Jan; 9(1):91-105. PubMed ID: 26558304
[TBL] [Abstract][Full Text] [Related]
9. Proteasome inhibitors for the treatment of multiple myeloma.
Scalzulli E; Grammatico S; Vozella F; Petrucci MT
Expert Opin Pharmacother; 2018 Mar; 19(4):375-386. PubMed ID: 29478351
[TBL] [Abstract][Full Text] [Related]
10. [Research Progress and Application of Daratumumab in Non-Multiple Myeloma--Review].
Gao F; Li F
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Oct; 31(5):1574-1578. PubMed ID: 37846719
[TBL] [Abstract][Full Text] [Related]
11. Current Phase II investigational proteasome inhibitors for the treatment of multiple myeloma.
Bringhen S; Gay F; Donato F; Troia R; Mina R; Palumbo A
Expert Opin Investig Drugs; 2014 Sep; 23(9):1193-209. PubMed ID: 24905450
[TBL] [Abstract][Full Text] [Related]
12. The effect of immunomodulatory drugs on bone metabolism of patients with multiple myeloma.
Liu Y; Li B; Chen X; Xiong H; Huang C
Expert Rev Hematol; 2024; 17(1-3):47-54. PubMed ID: 38319240
[TBL] [Abstract][Full Text] [Related]
13. Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going?
Thanendrarajan S; Davies FE; Morgan GJ; Schinke C; Mathur P; Heuck CJ; Zangari M; Epstein J; Yaccoby S; Weinhold N; Barlogie B; van Rhee F
Immunotherapy; 2016; 8(3):367-84. PubMed ID: 26888183
[TBL] [Abstract][Full Text] [Related]
14. SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies.
Deckert J; Wetzel MC; Bartle LM; Skaletskaya A; Goldmacher VS; Vallée F; Zhou-Liu Q; Ferrari P; Pouzieux S; Lahoute C; Dumontet C; Plesa A; Chiron M; Lejeune P; Chittenden T; Park PU; Blanc V
Clin Cancer Res; 2014 Sep; 20(17):4574-83. PubMed ID: 24987056
[TBL] [Abstract][Full Text] [Related]
15. Proteasome inhibitors: structure and function.
Nunes AT; Annunziata CM
Semin Oncol; 2017 Dec; 44(6):377-380. PubMed ID: 29935898
[TBL] [Abstract][Full Text] [Related]
16. Salvage therapy of multiple myeloma: the new generation drugs.
Romano A; Conticello C; Cavalli M; Vetro C; Di Raimondo C; Di Martina V; Schinocca E; La Fauci A; Parrinello NL; Chiarenza A; Di Raimondo F
Biomed Res Int; 2014; 2014():456037. PubMed ID: 24967371
[TBL] [Abstract][Full Text] [Related]
17. A review on the treatment of multiple myeloma with small molecular agents in the past five years.
Zhang Z; Liu X; Zhao L; Zhou Y; Shi J; Chen W; Li J
Eur J Med Chem; 2022 Feb; 229():114053. PubMed ID: 34974338
[TBL] [Abstract][Full Text] [Related]
18. The immunoproteasome as a therapeutic target for hematological malignancies.
Miller Z; Lee W; Kim KB
Curr Cancer Drug Targets; 2014; 14(6):537-48. PubMed ID: 25059201
[TBL] [Abstract][Full Text] [Related]
19. New Drugs in Multiple Myeloma.
Kunacheewa C; Orlowski RZ
Annu Rev Med; 2019 Jan; 70():521-547. PubMed ID: 30691369
[TBL] [Abstract][Full Text] [Related]
20. Novel targeted therapies and combinations for the treatment of multiple myeloma.
Agarwal A; Mahadevan D
Cardiovasc Hematol Disord Drug Targets; 2013 Mar; 13(1):2-15. PubMed ID: 22882073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
